New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JBL;ARRS;GOOG;NYX;ICE;SD;ACN;BBBY;FOLD;GSK;MDRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 >>
August 21, 2015
17:40 EDTGOOGEU intensifies Google antitrust investigation, WSJ reports
The European Union is deepening its probe into allegations that Google abuses its dominance in advertising contracts with website operators and copies content from its competitors, the Wall Street Journal reports. Reference Link
13:50 EDTGOOGOn The Fly: Weekly technical notes, Gold, S&P 500, Germany, China, Energy
Subscribe for More Information
13:38 EDTGOOGGoogle says brings tweets to mobile Google search app, desktop
In May, Google announced that it was bringing Tweets to Google Search on mobile devices. The company today updated the blog entry to say that it has "extended this to the desktop now, too, and in English everywhere." Reference Link
11:12 EDTGOOGQualcomm reportedly to enter consumer drone market
Subscribe for More Information
10:34 EDTGOOGSamsung working on Android tablet with 18.4-inch display, Sam Mobile reports
Subscribe for More Information
08:11 EDTGOOGDaimler AG could collaborate with Google, Apple, Reuters says
Subscribe for More Information
06:18 EDTGOOGGoogle's Brin says life sciences group to become standalone company
Subscribe for More Information
06:01 EDTGOOGABI Research: Portable PC sales to remain flat in 2015, DigiTimes says
Subscribe for More Information
05:55 EDTGOOGGoogle building EUR150M data center in West Dublin, Independent.ie reports
Google is investing EUR150M to build a new data center in West Dublin, Ireland, Independent.ie reports. The first construction phase, which will create 400 jobs, is expected to be completed later this year. Reference Link
05:25 EDTGSKNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
<< 1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use